|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...1920212223242526272829...39313932» |
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Journal: Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC. (Pubmed Central) - Sep 21, 2024
No abstract available
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma. (Pubmed Central) - Sep 21, 2024
No abstract available BV + CsA demonstrated modest activity in BV-refractory r/r HL; however, toxicity is substantial.
- || Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Retrospective data, Review, Journal: Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. (Pubmed Central) - Sep 21, 2024
Regimens with ponatinib elicited higher molecular response rates than those with other TKIs. The high response and survival rates achieved with blinatumomab plus TKIs and steroids suggest that further studies are required to assess the need for intensive treatments such as chemotherapy or stem cell transplant in these patients.
- | Talvey (talquetamab-tgvs) / J&J
Journal: Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. (Pubmed Central) - Sep 21, 2024
P1, P2
With appropriate education and support, health care practitioners can ensure patients with RRMM maintain quality of life and treatment adherence. VIDEO ABSTRACT.
- ||| Empliciti (elotuzumab) / AbbVie, BMS, Opdivo (nivolumab) / BMS
P3 data, Journal: Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study. (Pubmed Central) - Sep 21, 2024
P3
VIDEO ABSTRACT. CheckMate 602 did not demonstrate clinical benefit of nivolumab (+/- elotuzumab) plus Pd versus Pd for patients with relapsed/refractory MM (RRMM).
- ||| Iomab-B (I-131-apamistamab) / Actinium, Immedica
P3 data, Journal: Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. (Pubmed Central) - Sep 21, 2024
P3
The 131I-apamistamab-led regimen was associated with a higher dCR rate than conventional care in older patients with RR AML. 131I-apamistamab was well tolerated and could address an unmet need in this population.
- || Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker: PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. (Pubmed Central) - Sep 21, 2024
PD-L1 and TILs may be predictive biomarkers for preoperative anti-PD1/RT response. Reduction in TILs after adding RT to anti-PD1 highlights the importance of treatment sequencing.
- | Ibrance (palbociclib) / Pfizer
Biomarker, Journal: Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). (Pubmed Central) - Sep 21, 2024
The CDK4/6 inhibitor palbociclib at 75 mg/m2 orally daily was tolerable in this heavily pretreated cohort. No objective responses were observed in this histology-agnostic biomarker-selected population with treatment-refractory solid tumors, demonstrating that pathway alteration alone is insufficient in pediatric cancers to generate a response to palbociclib monotherapy.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Adjuvant treatment for renal cell carcinoma: current status and future. (Pubmed Central) - Sep 21, 2024
Currently, there is no role for adjuvant tyrosine-kinase inhibitors and radiotherapy for RCC. Meanwhile, a multidisciplinary approach and shared decision-making should be adopted.
- | gemcitabine / Generic mfg.
Biomarker, Journal: Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer. (Pubmed Central) - Sep 21, 2024
Cancer cell stemness was ascertained to be highly relevant to NANOG overexpression that can be abrogated by synergized gemcitabine-drug combinations. Therefore, NANOG works as a therapeutic biomarker for predicating efficient combinatorial treatment of gemcitabine in pancreatic cancer.
- | albumin-bound paclitaxel / Generic mfg.
Journal: Peripheral neurotoxicity induced by albumin-bound paclitaxel: a case report. (Pubmed Central) - Sep 21, 2024
Therefore, NANOG works as a therapeutic biomarker for predicating efficient combinatorial treatment of gemcitabine in pancreatic cancer. After four treatment cycles, the tumor treatment was evaluated as partial response (PR), and the tumor lesion became 2.9
- ||| Forteca (prolgolimab) / Biocad
P3 data, Journal, Metastases: A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT). (Pubmed Central) - Sep 21, 2024
P2, P3
The immunogenicity study did not detect binding antibodies to prolgolimab in any of the subjects. The obtained results showed that the selected fixed dosing regimen of prolgolimab 250 mg Q3W is characterized by efficacy and safety parameters comparable to that observed for the 1 mg/kg Q2W regimen.
- | Journal: Perspectives on the clinical use of anti-amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology. (Pubmed Central) - Sep 21, 2024
While the era of disease-modifying therapies for AD is now in its infancy, there is an expectation that these discoveries will be followed by improved therapies and combination treatments leading to greater efficacy in ameliorating the clinical trajectory of AD. Anti-amyloid therapy costs are comparable to other commonly used biologics.Anti-amyloid therapy efficacy is comparable to other commonly used biologics.Anti-amyloid therapy safety is compatible with other commonly used biologics.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Clinical, Journal, Real-world evidence, Real-world: Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. (Pubmed Central) - Sep 21, 2024
Preliminary analyses suggest that some prognostic factors differ between viral and nonviral patients, potentially due to biological and immunological differences. Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice.
- | NI-1801 / Light Chain Biosci
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers (clinicaltrials.gov) - Sep 21, 2024
P1, N=70, Recruiting, Sponsor: Light Chain Bioscience - Novimmune SA
Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice. N=40 --> 70 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> May 2026
- | PF-07826390 / Pfizer
Phase classification, Metastases: A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov) - Sep 20, 2024
P1, N=190, Not yet recruiting, Sponsor: Pfizer
N=40 --> 70 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> May 2026 Phase classification: P1/2 --> P1
- ||| RP2 / Replimune
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Oncolytic virus, Metastases: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC (clinicaltrials.gov) - Sep 20, 2024
P2, N=30, Recruiting, Sponsor: Replimune Inc.
Phase classification: P1/2 --> P1 Not yet recruiting --> Recruiting | N=60 --> 30 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Dec 2027
- ||||| Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Rituxan (rituximab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: SUNMO: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 20, 2024
P3, N=222, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | N=60 --> 30 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Dec 2027 Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2025 --> Feb 2025
- || Keytruda (pembrolizumab) / Merck (MSD), INBRX-106 / Inhibrx Biosci
Enrollment open, Trial primary completion date, Combination therapy: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov) - Sep 20, 2024
P2, N=12, Recruiting, Sponsor: Providence Health & Services
Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2025 --> Feb 2025 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2026 --> Jun 2027
- | bintrafusp alfa (M7824) / EMD Serono
Trial primary completion date: Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). (clinicaltrials.gov) - Sep 20, 2024
P2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2026 --> Jun 2027 Trial primary completion date: Aug 2024 --> Aug 2025
- ||| modakafusp alfa (TAK-573) / Takeda
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: iinnovate-3: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=15, Completed, Sponsor: Takeda
Trial primary completion date: Aug 2024 --> Aug 2025 Active, not recruiting --> Completed | N=58 --> 15 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024
- || Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Enrollment open, Combination therapy, Metastases: A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients (clinicaltrials.gov) - Sep 20, 2024
P2, N=24, Recruiting, Sponsor: Georgetown University
Active, not recruiting --> Completed | N=58 --> 15 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024 Suspended --> Recruiting
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
PK/PD data, Journal: Estimation of CDK inhibitors by RP-HPLC: application for pharmacokinetic interactions studies with PPIs. (Pubmed Central) - Sep 20, 2024
The RP-HPLC method was used to analyze in vitro and in vivo samples. Long-term treatment with PPIs affects pharmacokinetics of palbociclib and ribociclib, necessitating optimal chemotherapy regimen.
- | AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial primary completion date, Metastases: COMUNITY: Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=50, Not yet recruiting, Sponsor: Mirror Biologics, Inc.
Long-term treatment with PPIs affects pharmacokinetics of palbociclib and ribociclib, necessitating optimal chemotherapy regimen. Trial primary completion date: Dec 2025 --> Mar 2026
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=184, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2025 --> Mar 2026 Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Real-world evidence, Real-world, Metastases: Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=20, Not yet recruiting, Sponsor: Fujian Provincial Hospital
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Surgery, Metastases: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 20, 2024
P1, N=95, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> May 2024
- || Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, evorpacept (ALX148) / ALX Oncology
Trial primary completion date, Combination therapy, Metastases: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=80, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> May 2024 Trial primary completion date: Sep 2024 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Treatment of Pembrolizumab-Induced Mucocutaneous Lichen Planus With Metronidazole. (Pubmed Central) - Sep 20, 2024
Trial primary completion date: Sep 2024 --> Dec 2024 No abstract available
- | Orencia (abatacept) / BMS
Trial primary completion date, Post-transplantation: Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD (clinicaltrials.gov) - Sep 20, 2024
P2, N=92, Recruiting, Sponsor: NYU Langone Health
No abstract available Trial primary completion date: Aug 2024 --> Aug 2025
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: TRIFLUOX-DP: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=73, Not yet recruiting, Sponsor: UNICANCER
Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Jun 2028 --> Oct 2028 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Oct 2026
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy, Metastases: TRITON: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Sep 20, 2024
P3, N=280, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2028 --> Oct 2028 | Initiation date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2026 --> Oct 2026 Trial completion date: Mar 2031 --> Aug 2033
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, FG-3246 / Fortis Therap, FibroGen
Phase classification, Combination therapy, Metastases: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=36, Recruiting, Sponsor: Rahul Aggarwal
Trial completion date: Mar 2031 --> Aug 2033 Phase classification: P1b/2 --> P1/2
- | Rituxan (rituximab) / Roche
New P2 trial: The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 20, 2024
P2, N=46, Recruiting, Sponsor: Cairo University
- || Tecentriq (atezolizumab) / Roche
Enrollment closed, Metastases: Neoadjuvant Atezolizumab in Cutaneous Melanoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=20, Active, not recruiting, Sponsor: The Methodist Hospital Research Institute
Phase classification: P1b/2 --> P1/2 Recruiting --> Active, not recruiting
- || Cyramza (ramucirumab) / Eli Lilly, Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
Review, Journal: Surgical indication and management of obstructive colonic metastasis from primary lung adenocarcinoma: report of a case and review of the literature. (Pubmed Central) - Sep 20, 2024
Recruiting --> Active, not recruiting In this case, surgical resection of colonic metastasis from primary lung adenocarcinoma may have contributed to the short-term prognosis as a bridge-to-next available multimodal treatment.
- | Darzalex (daratumumab) / J&J
Journal: Newly diagnosed multiple myeloma with bleeding and coagulation abnormalities caused by a thrombin-inhibiting substance. (Pubmed Central) - Sep 20, 2024
Therefore, we believe that the diagnosis and the treatment course of this case provide valuable information. Moreover, such case reports provide significant insights into the pathophysiology of bleeding complications associated with MM.
- | Rituxan (rituximab) / Roche
Journal: Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab. (Pubmed Central) - Sep 20, 2024
This report describes the case of a 70-year-old PMN patient with extremely high aPLA2R titer who failed to respond to very high doses of RTX. We also discuss the possible reasons for treatment failure.
- | Imfinzi (durvalumab) / AstraZeneca, Orpathys (savolitinib) / AstraZeneca, Hutchmed
Trial completion date, Trial primary completion date, Metastases: Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) (clinicaltrials.gov) - Sep 20, 2024
P2, N=25, Recruiting, Sponsor: Jeeyun Lee
We also discuss the possible reasons for treatment failure. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- || Yuanruida (inaticabtagene autoleucel) / CASI
Trial primary completion date: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=60, Recruiting, Sponsor: Juventas Cell Therapy Ltd.
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial primary completion date: Jun 2024 --> Dec 2024
- | Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date: Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=117, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- | Kaitanni (cadonilimab) / Akesobio, Fumena (vorolanib) / Tyrogenex
New trial, Metastases: A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial: A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM (clinicaltrials.gov) - Sep 20, 2024
P2, N=20, Recruiting, Sponsor: Shanghai 6th People's Hospital
- ||| Zynyz (retifanlimab-dlwr) / Incyte
Enrollment closed, Enrollment change, Combination therapy, Metastases: POD1UM-204: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (clinicaltrials.gov) - Sep 20, 2024
P2, N=206, Active, not recruiting, Sponsor: Incyte Corporation
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024 Recruiting --> Active, not recruiting | N=300 --> 206
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Retrospective data, Journal, CAR T-Cell Therapy, Real-world evidence, Real-world: Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven. (Pubmed Central) - Sep 20, 2024
Our real-world data show high and durable response rates, with a non-significant trend towards a higher efficacy and higher toxicity for axi-cel compared to tisa-cel. Our results are in line with other real-world registries except for a shorter median OS and more high-grade ICANS.
- | Opdivo (nivolumab) / BMS
Biomarker, Journal: Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer. (Pubmed Central) - Sep 20, 2024
We developed and validated a prognostic model for patients with bladder cancer who underwent RC. This model will be beneficial in identifying patients with poor prognosis and those who are potential candidates for clinical trials of adjuvant therapy.
- | magrolimab (ONO-7913) / Ono Pharma
Trial completion date, Combination therapy, Metastases: ELEVATE TNBC: Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Sep 20, 2024
P2, N=92, Active, not recruiting, Sponsor: Gilead Sciences
This model will be beneficial in identifying patients with poor prognosis and those who are potential candidates for clinical trials of adjuvant therapy. Trial completion date: Jan 2025 --> Oct 2024
- ||| Opdivo (nivolumab) / BMS
Trial completion date, Metastases: CheckMate 078: Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2024
P3, N=639, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2025 --> Oct 2024 Trial completion date: May 2023 --> Nov 2023
- | Hansizhuang (serplulimab) / Fosun Pharma
Biomarker, New P2 trial, Metastases: Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC (clinicaltrials.gov) - Sep 20, 2024
P2, N=90, Recruiting, Sponsor: Fujian Medical University Union Hospital
- || rogaratinib (BAY 1163877) / Bayer
Trial completion, Combination therapy, Metastases: FORT-2: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=37, Completed, Sponsor: Bayer
Trial completion date: May 2023 --> Nov 2023 Active, not recruiting --> Completed